한글목차

항생제 시장은 2022-2027년간 99억 811만 달러 확대되고, 예측 기간중 연평균 복합 성장률(CAGR)은 4.21%를 나타낼 것으로 예측됩니다.

항생제 시장에 대한 전체적인 분석, 시장 규모와 예측, 동향, 시장 성장 촉진요인 및 촉진요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 게재했습니다.

현재의 시장 시나리오, 최신 동향과 성장요인, 시장 환경 전체에 관한 최신 분석을 제공합니다. 세균 감염증 유병률 증가, 세균에 기인한 다양한 질환과 그 치료에 대한 의식 고양, 세계 고령화율 상승에 힘입어 시장 성장이 가속화되고 있습니다.

본 조사에서는 항생제 나노테크놀러지 응용이 향후 몇 년간 항생제 시장 성장을 가속하는 주요인 중 하나로 들고 있습니다. 또한 연령에 응한 항생제 연구개발에 대한 우선순위 증가, 제휴·협력 증가가 시장의 큰 수요로 연결됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 생태계

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모(2022년)
• 시장 전망(2022-2027년)

제4장 시장 규모 실적

• 항생제 세계 시장(2017-2021년)
• 투여 경로별 부문 분석(2017-2021년)
• 약제 클래스별 부문 분석(2017-2021년)
• 지역별 부문 분석(2017-2021년)
• 국가별 부문 분석(2017-2021년)

제5장 Five Forces 분석

• Five Forces 요약
• 바이어의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁 위협
• 시장 현황

제6장 시장 세분화 : 투여 경로별

• 시장 부문
• 비교 : 투여 경로별
• 정맥내 : 시장 규모와 예측(2022-2027년)
• 어랄 : 시장 규모와 예측(2022-2027년)
• 기타 : 시장 규모와 예측(2022-2027년)
• 시장 기회 : 투여 경로별

제7장 시장 세분화 : 약제 클래스별

• 시장 부문
• 비교 약제 클래스별
• B-lactam : 시장 규모와 예측(2022-2027년)
• Quinolones : 시장 규모와 예측(2022-2027년)
• Macrolids : 시장 규모와 예측(2022-2027년)
• Tetracyclins : 시장 규모와 예측(2022-2027년)
• 기타 : 시장 규모와 예측(2022-2027년)
• 시장 기회 : 약제 클래스별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 아시아 : 시장 규모와 예측(2022-2027년)
• 북미 : 시장 규모와 예측(2022-2027년)
• 유럽 : 시장 규모와 예측(2022-2027년)
• 세계 기타 지역 : 시장 규모와 예측(2022-2027년)
• 미국 : 시장 규모와 예측(2022-2027년)
• 중국 : 시장 규모와 예측(2022-2027년)
• 독일 : 시장 규모와 예측(2022-2027년)
• 일본 : 시장 규모와 예측(2022-2027년)
• 영국 : 시장 규모와 예측(2022-2027년)
• 시장 기회 : 지역별

제10장 성장 촉진요인, 과제 및 동향

• 시장 성장 촉진요인
• 시장이 해결해야 할 과제
• 성장 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란 상황
• 업계 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• AbbVie Inc.
• Bayer AG
• Bristol Myers Squibb Co.
• Cipla Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Kyorin Pharmaceutical Co. Ltd.
• Lupin Ltd.
• Merck KGaA
• Novartis AG
• Paratek Pharmaceuticals Inc.
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

제13장 부록

영문목차

The antibacterial drugs market is forecasted to grow by USD 9908.11 mn during 2022-2027, accelerating at a CAGR of 4.21% during the forecast period. The report on the antibacterial drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of bacterial infections, growing awareness of various diseases and their treatment caused by bacteria, and rising aging population globally.

Technavio's antibacterial drugs market is segmented as below:

By Route Of Administration

• Intravenous
• Oral
• Others

By Drug Class

• B-lactam
• Quinolones
• Macrolides
• Tetracyclines
• Others

By Geography

• Asia
• North America
• Europe
• Rest of World (ROW)

This study identifies the application of nanotechnology in antibacterial drugs as one of the prime reasons driving the antibacterial drugs market growth during the next few years. Also, rising priorities for research and development of age-appropriate antibiotics and increasing number of partnerships and collaborations will lead to sizable demand in the market.

The report on the antibacterial drugs market covers the following areas:

• Antibacterial drugs market sizing
• Antibacterial drugs market forecast
• Antibacterial drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antibacterial drugs market vendors that include AbbVie Inc., Basilea Pharmaceutica Ltd., Bayer AG, Binnopharm Group LLC, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Kyorin Pharmaceutical Co. Ltd., Lupin Ltd., Merck KGaA, Novartis AG, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Melinta Therapeutics LLC, and Shionogi and Co. Ltd.. Also, the antibacterial drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market by Geography
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global antibacterial drugs market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on global antibacterial drugs market 2017 - 2021 ($ million)
• 4.2 Route of administration Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Route of administration Segment 2017 - 2021 ($ million)
• 4.3 Drug class Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Drug class Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

• 6.1 Market segments
• Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
• 6.2 Comparison by Route of Administration
• Exhibit 32: Chart on Comparison by Route of Administration
• Exhibit 33: Data Table on Comparison by Route of Administration
• 6.3 Intravenous - Market size and forecast 2022-2027
• Exhibit 34: Chart on Intravenous - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Intravenous - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Intravenous - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Intravenous - Year-over-year growth 2022-2027 (%)
• 6.4 Oral - Market size and forecast 2022-2027
• Exhibit 38: Chart on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Oral - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Oral - Year-over-year growth 2022-2027 (%)
• 6.5 Others - Market size and forecast 2022-2027
• Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)
• 6.6 Market opportunity by Route of Administration
• Exhibit 46: Market opportunity by Route of Administration ($ million)
• Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

• 7.1 Market segments
• Exhibit 48: Chart on Drug Class - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Drug Class - Market share 2022-2027 (%)
• 7.2 Comparison by Drug Class
• Exhibit 50: Chart on Comparison by Drug Class
• Exhibit 51: Data Table on Comparison by Drug Class
• 7.3 B-lactam - Market size and forecast 2022-2027
• Exhibit 52: Chart on B-lactam - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on B-lactam - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on B-lactam - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on B-lactam - Year-over-year growth 2022-2027 (%)
• 7.4 Quinolones - Market size and forecast 2022-2027
• Exhibit 56: Chart on Quinolones - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Quinolones - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Quinolones - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Quinolones - Year-over-year growth 2022-2027 (%)
• 7.5 Macrolids - Market size and forecast 2022-2027
• Exhibit 60: Chart on Macrolids - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Data Table on Macrolids - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Chart on Macrolids - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Macrolids - Year-over-year growth 2022-2027 (%)
• 7.6 Tetracyclins - Market size and forecast 2022-2027
• Exhibit 64: Chart on Tetracyclins - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Data Table on Tetracyclins - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Chart on Tetracyclins - Year-over-year growth 2022-2027 (%)
• Exhibit 67: Data Table on Tetracyclins - Year-over-year growth 2022-2027 (%)
• 7.7 Others - Market size and forecast 2022-2027
• Exhibit 68: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 71: Data Table on Others - Year-over-year growth 2022-2027 (%)
• 7.8 Market opportunity by Drug Class
• Exhibit 72: Market opportunity by Drug Class ($ million)
• Exhibit 73: Data Table on Market opportunity by Drug Class ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 75: Chart on Market share by geography 2022-2027 (%)
• Exhibit 76: Data Table on Market share by geography 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 77: Chart on Geographic comparison
• Exhibit 78: Data Table on Geographic comparison
• 9.3 Asia - Market size and forecast 2022-2027
• Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.4 North America - Market size and forecast 2022-2027
• Exhibit 83: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.5 Europe - Market size and forecast 2022-2027
• Exhibit 87: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 95: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 China - Market size and forecast 2022-2027
• Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
• 9.9 Germany - Market size and forecast 2022-2027
• Exhibit 103: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 104: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 105: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.10 Japan - Market size and forecast 2022-2027
• Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• 9.11 UK - Market size and forecast 2022-2027
• Exhibit 111: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 112: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 113: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 114: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity by geography
• Exhibit 115: Market opportunity by geography ($ million)
• Exhibit 116: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 117: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 119: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 120: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 121: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 122: Matrix on vendor position and classification
• 12.3 AbbVie Inc.
• Exhibit 123: AbbVie Inc. - Overview
• Exhibit 124: AbbVie Inc. - Product / Service
• Exhibit 125: AbbVie Inc. - Key news
• Exhibit 126: AbbVie Inc. - Key offerings
• 12.4 Bayer AG
• Exhibit 127: Bayer AG - Overview
• Exhibit 128: Bayer AG - Business segments
• Exhibit 129: Bayer AG - Key news
• Exhibit 130: Bayer AG - Key offerings
• Exhibit 131: Bayer AG - Segment focus
• 12.5 Bristol Myers Squibb Co.
• Exhibit 132: Bristol Myers Squibb Co. - Overview
• Exhibit 133: Bristol Myers Squibb Co. - Product / Service
• Exhibit 134: Bristol Myers Squibb Co. - Key news
• Exhibit 135: Bristol Myers Squibb Co. - Key offerings
• 12.6 Cipla Ltd.
• Exhibit 136: Cipla Ltd. - Overview
• Exhibit 137: Cipla Ltd. - Business segments
• Exhibit 138: Cipla Ltd. - Key news
• Exhibit 139: Cipla Ltd. - Key offerings
• Exhibit 140: Cipla Ltd. - Segment focus
• 12.7 Eli Lilly and Co.
• Exhibit 141: Eli Lilly and Co. - Overview
• Exhibit 142: Eli Lilly and Co. - Product / Service
• Exhibit 143: Eli Lilly and Co. - Key news
• Exhibit 144: Eli Lilly and Co. - Key offerings
• 12.8 F. Hoffmann La Roche Ltd.
• Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
• 12.9 GlaxoSmithKline Plc
• Exhibit 150: GlaxoSmithKline Plc - Overview
• Exhibit 151: GlaxoSmithKline Plc - Business segments
• Exhibit 152: GlaxoSmithKline Plc - Key news
• Exhibit 153: GlaxoSmithKline Plc - Key offerings
• Exhibit 154: GlaxoSmithKline Plc - Segment focus
• 12.10 Kyorin Pharmaceutical Co. Ltd.
• Exhibit 155: Kyorin Pharmaceutical Co. Ltd. - Overview
• Exhibit 156: Kyorin Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 157: Kyorin Pharmaceutical Co. Ltd. - Key offerings
• 12.11 Lupin Ltd.
• Exhibit 158: Lupin Ltd. - Overview
• Exhibit 159: Lupin Ltd. - Product / Service
• Exhibit 160: Lupin Ltd. - Key news
• Exhibit 161: Lupin Ltd. - Key offerings
• 12.12 Merck KGaA
• Exhibit 162: Merck KGaA - Overview
• Exhibit 163: Merck KGaA - Business segments
• Exhibit 164: Merck KGaA - Key news
• Exhibit 165: Merck KGaA - Key offerings
• Exhibit 166: Merck KGaA - Segment focus
• 12.13 Novartis AG
• Exhibit 167: Novartis AG - Overview
• Exhibit 168: Novartis AG - Business segments
• Exhibit 169: Novartis AG - Key offerings
• Exhibit 170: Novartis AG - Segment focus
• 12.14 Paratek Pharmaceuticals Inc.
• Exhibit 171: Paratek Pharmaceuticals Inc. - Overview
• Exhibit 172: Paratek Pharmaceuticals Inc. - Product / Service
• Exhibit 173: Paratek Pharmaceuticals Inc. - Key offerings
• 12.15 Pfizer Inc.
• Exhibit 174: Pfizer Inc. - Overview
• Exhibit 175: Pfizer Inc. - Product / Service
• Exhibit 176: Pfizer Inc. - Key news
• Exhibit 177: Pfizer Inc. - Key offerings
• 12.16 Sanofi
• Exhibit 178: Sanofi - Overview
• Exhibit 179: Sanofi - Business segments
• Exhibit 180: Sanofi - Key news
• Exhibit 181: Sanofi - Key offerings
• Exhibit 182: Sanofi - Segment focus
• 12.17 Teva Pharmaceutical Industries Ltd.
• Exhibit 183: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 184: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 185: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 186: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 187: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 188: Inclusions checklist
• Exhibit 189: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 190: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 191: Research methodology
• Exhibit 192: Validation techniques employed for market sizing
• Exhibit 193: Information sources
• 13.5 List of abbreviations
• Exhibit 194: List of abbreviations